Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Reckitt unit hit with $60 million verdict in Enfamil baby formula case in Illinois

Published 03/15/2024, 06:58 PM
Updated 03/15/2024, 07:21 PM
© Reuters.

By Brendan Pierson

(Reuters) - An Illinois jury has ordered Reckitt Benckiser (LON:RKT) unit Mead Johnson to pay $60 million to the mother of a premature baby who died of an intestinal disease after being fed the company's Enfamil baby formula.

The jury in an Illinois state court in St. Clair County on Wednesday found that Mead Johnson was negligent and that it failed to warn of the risk of necrotizing enterocolitis (NEC). The disease, which causes the death of bowel tissue, mostly affects premature newborns and has a fatality rate of about 15% to 40%.

The $60 million verdict includes compensation for plaintiff Jasmine Watson's loss and grief, and for the pain and suffering of her baby, Chance Dean.

The verdict comes in the first trial out of hundreds of lawsuits claiming that various Enfamil and Abbott Laboratories (NYSE:ABT)' Similac formulas caused NEC.

According to the U.S. National Institutes of Health, there is evidence that formula increases the risk of NEC in premature infants compared with breast milk.

"This verdict confirms what Mead Johnson has known for years: cow's-milk based baby formula causes NEC in preterm infants, often with fatal consequences," Ben Whiting, a lawyer for Watson, said in a statement.

Mead Johnson said in a statement that it was disappointed with the verdict and would appeal it.

"We continue to believe that the allegations from the plaintiff's lawyers in this case were not supported by the science or experts in the medical community," it said.

More than 400 NEC lawsuits against Mead Johnson and Abbott are pending in federal court in Chicago, and others, like Watson's are in state courts.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Plaintiffs in the cases say that the companies concealed the fact that their formula, including products made specifically for premature infants and others, was riskier than alternatives like donor milk.

The companies have denied the allegations.

The NEC lawsuits are separate from ongoing litigation against Abbott over the shutdown of its Sturgis, Michigan, plant and subsequent recall of batches of baby formula for possible contamination, which contributed to a nationwide formula shortage in 2022.

Abbott has denied that it distributed tainted formula.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.